Literature DB >> 29940185

Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.

Mitchell R O'Connell1.   

Abstract

Prokaryotic adaptive immune systems use Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) and CRISPR-associated (Cas) proteins for RNA-guided cleavage of foreign genetic elements. The focus of this review, Type VI CRISPR-Cas systems, contain a single protein, Cas13 (formerly C2c2) that when assembled with a CRISPR RNA (crRNA) forms a crRNA-guided RNA-targeting effector complex. Type VI CRISPR-Cas systems can be divided into four subtypes (A-D) based on Cas13 phylogeny. All Cas13 proteins studied to date possess two enzymatically distinct ribonuclease activities that are required for optimal interference. One RNase is responsible for pre-crRNA processing to form mature Type VI interference complexes, while the other RNase activity provided by the two Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) domains, is required for degradation of target-RNA during viral interference. In this review, I will compare and contrast what is known about the molecular architecture and behavior of Type VI (A-D) CRISPR-Cas13 interference complexes, how this allows them to carry out their RNA-targeting function, how Type VI accessory proteins are able to modulate Cas13 activity, and how together all of these features have led to the rapid development of a range of RNA-targeting applications. Throughout I will also discuss some of the outstanding questions regarding Cas13's molecular behavior, and its role in bacterial adaptive immunity and RNA-targeting applications.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C2c2; CRISPR–Cas immunity; Cas13; Type VI CRISPR–Cas systems; programmable RNA targeting

Year:  2018        PMID: 29940185     DOI: 10.1016/j.jmb.2018.06.029

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  74 in total

Review 1.  Current strategies for Site-Directed RNA Editing using ADARs.

Authors:  Maria Fernanda Montiel-Gonzalez; Juan Felipe Diaz Quiroz; Joshua J C Rosenthal
Journal:  Methods       Date:  2018-11-29       Impact factor: 3.608

2.  Programmable RNA-Guided RNA Effector Proteins Built from Human Parts.

Authors:  Simone Rauch; Emily He; Michael Srienc; Huiqing Zhou; Zijie Zhang; Bryan C Dickinson
Journal:  Cell       Date:  2019-06-20       Impact factor: 41.582

Review 3.  Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.

Authors:  Tina Y Liu; Jennifer A Doudna
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

4.  Diagnosis of COVID-19, vitality of emerging technologies and preventive measures.

Authors:  Muhammad Asif; Yun Xu; Fei Xiao; Yimin Sun
Journal:  Chem Eng J       Date:  2021-05-07       Impact factor: 13.273

Review 5.  The potential of engineered eukaryotic RNA-binding proteins as molecular tools and therapeutics.

Authors:  Carl R Shotwell; John D Cleary; J Andrew Berglund
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-11-03       Impact factor: 9.957

Review 6.  Emerging role of nanomedicine in the treatment of neuropathic pain.

Authors:  Pankaj Bidve; Namrata Prajapati; Kiran Kalia; Rakesh Tekade; Vinod Tiwari
Journal:  J Drug Target       Date:  2019-07-22       Impact factor: 5.121

7.  It takes two (Las1 HEPN endoribonuclease domains) to cut RNA correctly.

Authors:  Monica C Pillon; Kevin H Goslen; Jacob Gordon; Melissa L Wells; Jason G Williams; Robin E Stanley
Journal:  J Biol Chem       Date:  2020-03-27       Impact factor: 5.157

Review 8.  CRISPR-Based Technologies: Impact of RNA-Targeting Systems.

Authors:  Michael P Terns
Journal:  Mol Cell       Date:  2018-11-01       Impact factor: 17.970

Review 9.  Therapeutic Genome Editing and In Vivo Delivery.

Authors:  Amanda Catalina Ramirez-Phillips; Dexi Liu
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

10.  Visualization and characterization of RNA-protein interactions in living cells.

Authors:  Ningjun Duan; Maria Arroyo; Wen Deng; M Cristina Cardoso; Heinrich Leonhardt
Journal:  Nucleic Acids Res       Date:  2021-10-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.